HealthTrust renews contrast media contract with Bayer HealthCare

HealthTrust Purchasing Group has renewed its three-year contract with Bayer HealthCare Pharmaceuticals to make the MR contrast agent, Magnevist Injection, available to members of the HealthTrust network.

The agreement, which was effective Sept. 1, extends through Aug. 31, 2010, and includes 5, 10, 15 and 20 mL single-dose vials, 50 and 100 mL pharmacy bulk packages, and 10, 15 and 20 mL pre-filled syringes of Magnevist.

HealthTrust Purchasing Group of Brentwood, Tennessee supports more than 1,300 not-for-profit and for-profit acute care hospitals, 430 ambulatory surgery centers, nearly 2,500 physician practices, as well as over 3,000 alternate care sites, according to Bayer.

"We are pleased that HealthTrust is continuing its long-standing relationship with Bayer HealthCare Pharmaceuticals. We value our association with HealthTrust, and consider the renewal of our agreement a testament to the quality of products we offer and to the outstanding customer service our sales force strives to provide to the HealthTrust membership and their patient community," said Douglas Stefanelli, vice president and general manager, Diagnostic Imaging, Bayer HeathCare.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.